Acumen Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Acumen Pharmaceuticals, Inc.

Aug-26	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences ABOS GlobeNewswire
Aug-12	Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights ABOS GlobeNewswire
Aug-05	Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 ABOS GlobeNewswire
Jul-28	Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025 ABOS GlobeNewswire
Jul-15	Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease ABOS GlobeNewswire
Jul-10	Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC) 2025 ABOS GlobeNewswire
May-13	Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights ABOS GlobeNewswire
May-07	Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference ABOS GlobeNewswire
May-06	Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 ABOS GlobeNewswire